Akeso Reveals Phase 2 Results for Ivonescimab Treatment
During a recent international conference, Akeso shared the Phase 2 clinical results of their innovative treatment, ivonescimab. This bispecific antibody targets PD-1 and VEGF, offering a new approach in oncology, especially for patients facing PD-L1-positive recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Notable Efficacy Observed in Trials
The results from this groundbreaking trial demonstrate significant and clinically meaningful reductions in tumor size, particularly for patients needing rapid intervention. When ivonescimab is combined with ligufalimab, there are further increases in tumor shrinkage and survival benefits compared to using ivonescimab alone. The preliminary efficacy results have shown considerable promise, exceeding previously established benchmarks in PD-1 studies.
Objective Response Rates and Disease Control
The clinical data reveals an objective response rate (ORR) of 30% for ivonescimab on its own. However, this number rises to an impressive 60% when it’s paired with ligufalimab. The disease control rate (DCR) follows a similar trend—80% for ivonescimab alone, increasing to 90% with ligufalimab's addition. These advancements highlight significant potential for patients moving from stable disease to partial response.
Progression-Free Survival Metrics
The median progression-free survival (mPFS) for those receiving ivonescimab as monotherapy was recorded at 5.0 months, with some patients achieving even better outcomes. For the combination treatment with ligufalimab, the mPFS reached an impressive 7.1 months, and the 6-month PFS rate was approximately 71.8%. These findings suggest a notable improvement in patient outcomes.
Safety Profile of Ivonescimab in Treatment
In addition to its efficacy, ivonescimab boasts a commendable safety profile. Data from the trials show that treatment-related adverse events (TRAE) did not result in any discontinuations or fatalities, regardless of whether patients received monotherapy or combined therapy with ligufalimab. This manageable safety profile is a promising indicator for the drug's potential in broader clinical use.
Future Directions and Comparisons with Existing Treatments
Although there are already approvals for PD-1 inhibitors combined with chemotherapy, some patients still face suboptimal responses. This highlights the urgent need for alternative treatment options. To address this, Akeso has initiated a phase 3 study that directly compares ivonescimab with ligufalimab to pembrolizumab in a first-line treatment approach for PD-L1 positive R/M HNSCC. This essential study could usher in a new era for effective cancer immunotherapies.
Frequently Asked Questions
What is ivonescimab?
Ivonescimab is a bispecific antibody created by Akeso, targeting PD-1 and VEGF to treat recurrent or metastatic head and neck squamous cell carcinoma.
What were the results of the Phase 2 trial?
The Phase 2 trial indicated that ivonescimab alone had a 30% objective response rate, which rose to 60% with ligufalimab.
How does the safety profile of ivonescimab compare to existing treatments?
Clinical trials showed that ivonescimab possesses a manageable safety profile, with no serious adverse events resulting in treatment discontinuation or death.
What is the significance of the ongoing phase 3 study?
This phase 3 study aims to evaluate ivonescimab combined with ligufalimab against pembrolizumab, potentially unveiling a more effective immunotherapy option for patients.
What does the future hold for Akeso and ivonescimab?
With encouraging results from ongoing studies, ivonescimab could significantly change treatment strategies for patients with recurrent or metastatic head and neck cancer.
